Psychedelic use is linked to a lower likelihood of migraines in a twin study, with within-pair analyses suggesting the association is not fully explained by shared genetics or family environment

Psychedelic use is associated with a lower likelihood of migraine in a twin study that compared people with and without lifetime use while accounting for shared genetic and family background. The finding points to a relationship that may extend beyond simple confounding by upbringing or inherited risk. Within twin pairs, the sibling who had used psychedelics was less likely to report migraine than the co-twin who had not, strengthening the signal beyond a basic population-level correlation. The design cannot prove causation, and factors such as personality, health behavior, or differences in the type, dose, and timing of psychedelic use could still matter. Migraine has long been discussed in relation to serotonergic psychedelics because of overlapping brain signaling pathways and anecdotal reports of headache relief or prevention. The result adds epidemiological evidence to that discussion and supports the need for more targeted clinical research on whether specific psychedelics could help prevent or reduce migraine symptoms.